CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients

Neoplasma

Volumn 57, Issue 6, 2010, Pages 512-521

  Ada, A O ^a   Kunak, S C ^b   Hancer, F ^a   Bilgen, S ^a   Suzen, S H ^a   Alpar, S ^c   Gulhan, M ^c,d   Kurt, B ^c,e   Iscan, M ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b GIRESUN UNIVERSITY   (Turkey)

^c Atatürk Chest Disease and Thoracic Surgery Education and Research Hospital   (Turkey)

^d UFUK UNIVERSITY   (Turkey)

^e ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

Author keywords

Cytochrome P 450; Glutathione S transferase; Non small cell lung cancer; Polymorphism; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; NAVELBINE; PACLITAXEL; CYP1B1 PROTEIN, HUMAN; CYTOCHROME P450; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; GSTP1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; EXON; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; GENETIC POLYMORPHISM; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 79952113910     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_06_512     Document Type: Article

References (58)

1. FIRAT D, CELIK I Cancer Statistics in Turkey and in the World 1993-1995. Turkish Association for the Cancer Research and Control. Ankara, 1998.
2. HOWE HL, WINGO PA, THUN MJ, RIES LA, ROSENBERG HM et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93: 824-842. doi:10.1093/ jnci/93.11.824
3. BUNN PA JR Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol. 2002; 20: 23S-33S.
4. GOKSEL T, AKKOCLU, A Turkish Thoracic Society, Lung and Pleural Malignancies Study Group. Pattern of Lung Cancer in Turkey, 1994-1998. Respiration 2002; 69: 207-210.
5. GOTO I, YONEDA S, YAMAMOTO M, KAWAJIRI K Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 1996; 56: 3725-3730.
6. KAWAJIRI K, EGUCHI H, NAKACHI K, SEKIYA T, YAMAMOTO M Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996; 56: 72-76.
7. SIEMIATYCKI J, KREWSKI D, FRANCO E, KAISERMAN M Association between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol 1995; 24: 504-514. doi:10.1093/ije/24.3.504
8. Turkish Ministry of Health, Cancer Prevention Unit Statistics, 2004.
9. BARTSCH H, CASTEGNARO M, ROJAS M, CAMUS AM, ALEXANDROV K et al. Expression of pulmonary cytochrome P4501A1 and carcinogen DNA adduct formation in high risk subjects for tobacco-related lung cancer. Tox Lett 1992; 64-65: 477-483. doi:10.1016/0378-4274(92)90222-6
10. KIM JH, STANSBURY KH, WALKER NJ, TURSH MA, STRICKLAND PT et al. Metabolism of benzo(a)pyrene and benzo(a)pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis 1998; 19: 1847-1853. doi:10.1093/carcin/ 19.10.1847
11. MICHAEL M, DOHERTY MM Drug metabolism by tumours: its nature, relevance and therapeutic implications. Expert Opin Drug Metab Toxicol 2007; 3: 783-803. doi:10.1517/ 17425255.3.6.783
12. CHANG JT, CHANG H, CHEN PH, LIN SL, LIN P Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer Res 2007; 13: 38-45. doi:10.1158/1078-0432. CCR-06-1166
13. HAYASHI S, WATANABE J, NAKACHI K, KAWAJIRI K Genetic linkage of lung cancer associated Msp 1 polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J Biochem 1991; 110: 407-411.
14. CASCORBI I, BROCKMÖLLER J, ROOTS I A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996; 56: 4965-4969.
15. SPIVACK SD, FASCO MJ, WALKER VE, KAMINSKY LS The molecular epidemiolgy of lung cancer. Crit Rev Toxicol 1997; 27: 319-365. doi:10.3109/10408449709089898
16. LE MARCHAND L, SIVARAMAN L, PIERCE L, SEIFRIED A, LUM A et al. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 1998; 58: 4858-4863.
17. SHIMADA T, WATANABE J, KAWAJIRI K, SUTTER TR, GUENGERICH FP et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999; 20: 1607-1613. doi:10.1093/carcin/20.8.1607
18. AKLILLU E, OSCARSON M, HIDESTRAND M, LEIDVIK B, OTTER C et al. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002; 61: 586-54. doi:10.1124/ mol.61.3.586
19. AKLILLU E, ØVREBØ S, BOTNEN IV, OTTER C, INGELMAN-SUNDBERG M Characterization of common CYP1B1 variants with different capacity for benzo(a)pyrene-7,8-dihydrodiol epoxide formation from benzo(a)pyrene. Cancer Res 2005; 65: 5105-5111. doi:10.1158/0008-5472.CAN-05-0113
20. WENZLAFF AS, COTE ML, BOCK CH, LAND SJ, SANTER SK et al. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 2005; 26: 2207-2212. doi:10.1093/carcin/bgi191
21. SHAH PP, SINGH AP, SINGH M, MATHUR N, MISHRA BN et al. Association of functionally important polymorphisms in cytochrome P4501B1 with lung cancer. Mutat Res 2008; 643: 4-10. doi:10.1016/j.mrfmmm.2008.05.001
22. ROTUNNO M, YU K, LUBIN JH, CONSONNI D, PESATORI AC et al. Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PLoS One 2009; 4: e5652. doi:10.1371/journal.pone.0005652
23. STRANGE RC, SPITERI MA, RAMACHANDRAN S, FRYER AA Glutathione S-transferase family of enzymes. Mutation Res 2001; 482: 21-26. doi:10.1016/S0027-5107(01)00206-8
24. NAKAGAWA K, YOKOTA J, WADA M, SASAKI Y, FUJIWARA Y et al. Level of glutathione S-transferase π mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. Jpn J Cancer Res 1988; 79: 301-304.
25. HOBAN PR, ROBSON CN, DAVIES SM, HALL AG, CATTAN RA et al. Reduced topoisomerase II and elevated alpha class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C. Biochem Pharmacol 1992; 43: 685-693. doi:10.1016/0006-2952(92)90231-7
26. SEIDEGARD J, EKSTROM G The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect 1997; 105 Suppl 4: 791-799. doi:10.2307/3433285
27. JOHANSSON AS, STENBERG G, WIDERSTEN M, MANNERVIK B Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. J Mol Biol 1998; 278: 687-698. doi:10.1006/jmbi.1998.1708
28. WATSON MA, STEWART RK, SMITH GB, MASSEY TE, BELL DA Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275-280. doi:10.1093/carcin/19.2.275
29. CURIGLIANO G, FERRETTI G, MANDALA M DE PAS T, CALABRO MG, SOLLi P et al. GSTM1, P53 and K-ras molecular, detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis. Anticancer Res 2001; 21: 3461-3469.
30. MATSUZOE D, HIDESHIMA T, IWASAKI A, YONEDA S, KAWAHARA K et al. Glutathione S-transferase mu1 null genotype is associated with K-ras gene mutation in lung adenocarcinoma among smokers. Carcinogenesis 2001; 21: 1327-1330. doi:10.1093/carcin/22.8.1327
31. PRZYGODZKI RM, BENNETT WP, GUINEE DG JR, KHAN MA, FREEDMAN A et al. Caporaso NE: p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP1E1 in surgically treated patients with non-small cell lung cancer. Pharmacogenetics 1998; 8: 503-511. doi:10.1097/00008571-199812000-00007
32. YANG P, YOKOMIZO A, TAZELAAR H. D, MARKS RS, LESNICK TG et al. Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. Lung Cancer 2002; 35: 221-229. doi:10.1016/S0169-5002(01)00426-3
33. SREEJA L, SYAMALA V, HARIHARAN S, SYAMALA VS, RAVEENDRAN PB et al. Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients. J Exp Ther Oncol 2008; 7: 73-85.
34. GE H, LAM WK, LEE J, WONG MP, YEW WW et al. Analysis of L-myc and GSTM1 genotypes in Chinese non-small cell lung carcinoma patients. Lung Cancer 1996; 15: 355-366. doi:10.1016/0169-5002(95)00598-6
35. SWEENEY C, NAZAR-STEWART V, STAPLETON PL, EATON DL, VAUGHAN TL Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003; 12: 527-533.
36. GONLUGUR U, PINARBASI H, GONLUGUR TE, SILIG Y The association between polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and lung cancer outcome. Cancer Invest 2006; 24: 497-501. doi:10.1080/ 07357900600814813
37. SWEENEY C, MCCLURE GY, FARES MY, STONE A, COLES BF et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile 105 Val polymorphism. Cancer Res 2000; 60: 5621-5624.
38. LU C, SPITZ MR, ZHAO H, DONG Q, TRUONG M et al. Association between Glutathione S-transferase π polymorphism and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 2006; 106: 441-447. doi:10.1002/ cncr.21619
39. BOOTON R, WARD T, HEIGHWAY J, ASHCROFT L, MORRIS J et al. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and nonsmall cell lung cancer. J Thorac Oncol 2006; 1: 679-683. doi:10.1097/01243894-200609000-00013
40. GANDARA DR, LARA PN, LAU DH, MACK P, GUMERLOCK PH Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach. Lung Cancer 2001; 34: S75-S80. doi:10.1016/S0169-5002(01)00368-3
41. COTE ML, YOO W, WENZLAFF AS, PRYSAK GM, SANTER SK et al. Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis. 2009; 30: 626-635. doi:10.1093/carcin/bgp033
42. World Health Organization: Histological typing of tumors. Tumori 67: 253-272, 1981
43. World Health Organization: WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
44. BAILEY LR, ROODI N, DUPONT WD, PARL FF Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998; 568: 5038-5041.
45. ABDEL-RAHMAN SZ, EL-ZEIN RA, ANWAR WA, AU WW A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett 1996; 107: 229-233. doi:10.1016/0304-3835(96)04832-X
46. PARK JY, SCHANTZ SP, STERN JC, KAUR T, LAZARUS P Association between glutathione S-transferase pi genetic polymorphisms and oral cancer risk. Pharmacogenetics 1999; 9: 497-504.
47. ZHENG W, JEFCOATE CR Steroidogenic factor-1 interacts with cAMP response element-binding protein to mediate cAMP stimulation of CYP1B1 via a far upstream enhancer. Mol Pharmacol 2005; 67: 499-512. doi:10.1124/ mol.104.005504
48. KO Y, ABEL J, HARTH V, BRÖDE P, ANTONY C et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001; 61: 4398-4404.
49. BANDIERA S, WEIDLICH S, HARTH V, BROEDE P, KO Y et al. Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 2005; 67: 435-443. doi:10.1124/mol.104.006056
50. MCGRATH M, HANKINSON SE, ARBEITMAN L, COLDITZ GA, HUNTER DJ Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 2004; 25: 559-565. doi:10.1093/carcin/bgh039
51. SISSUNG TM, PRICE DK, SPARREBOOM A, FIGG WD Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 2006; 4: 135-150. doi:10.1158/1541-7786.MCR-05-0101
52. DE VIVO I, HANKINSON SE, LI L, COLDITZ GA, HUNTER DJ Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 489-492.
53. VRANA D, NOVOTNY J, HOLCATOVA I, HLAVATA I, SOUCEK P CYP1B1 gene polymorphism modifies pancreatic cancer risk but not survival. Neoplasma 2010; 57: 15-19. doi:10.4149/neo_2010_01_015
54. KAUR-KNUDSEN D, NORDESTGAARD BG, TYBJAERGHANSEN A, BOJESEN SE CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease and cancer in 50000 individuals. Pharmacogenet Genomics 2009; 19: 685-694. doi:10.1097/FPC.0b013e32833042cb
55. HIRATA S, ODAJIMA T, KOHAMA G, ISHIGAKI S, NIITSU Y Significance of glutathione S-transferase-pi as a tumor marker in patients with oral cancer. Cancer 1992; 70: 2381-2387. doi:10.1002/1097-0142(19921115)70:10<2381:: AIDCNCR2820701002>3.0.CO;2-9
56. BAN N, TAKAHASHI Y, TAKAYAMA T, KURA T, KATAHIRA T et al. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 1996; 56: 3577-3582.
57. BEEGHLY A, KATSAROS D, CHEN H, FRACCHIOLI S, ZHANG Y et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 2006; 100: 330-337. doi:10.1016/j.ygyno.2005.08.035
58. OKCU MF, SELVAN M, WANG LE, STOUT L, ERANA R, et al. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 2004; 10: 2618-2625. doi:10.1158/1078-0432.CCR-03-0053